Answers are grounded in this paper and cite their sources.
Demonstrates targeted therapy for Alzheimer's disease using Angiopep2-conjugated Semorinemab, suggesting enhanced treatment potential.
Alzheimer's disease (AD) remains a major neurodegenerative disorder with limited effective treatments due to poor blood-brain barrier (BBB) penetration of therapeutic antibodies. This study proposes a novel targeted drug delivery system combining Angiopep2-conjugated Semorinemab loaded into Tau Vault nanocarriers. Angiopep2 facilitates receptor-mediated transcytosis across the BBB via LRP-1 receptors, while Tau Vaults provide biocompatible, stable encapsulation and controlled release of Semorinemab, a humanized anti-tau antibody. Our approach aims to enhance brain delivery efficiency, reduce systemic side effects, and improve therapeutic outcomes in AD models. This nanocarrier platform represents a promising strategy for precision delivery of biologics to the central nervous system. This preprint presents the conceptual framework, design rationale, and preliminary data supporting the development of Angiopep2-Semorinemab Tau Vaults as a next-generation therapy for Alzheimer's disease.
No takes yet. Share an insight, caveat, or question.
Bakr et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: